Showing 2131-2140 of 2319 results for "".
- Restylane Lyft Approved for Cheek Augmentation and Midface Contour Deficiencieshttps://practicaldermatology.com/news/restylane-lyft-approved-for-cheek-augmentation-and-midface-contour-deficiencies/2458917/The FDA approved Galderma's Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane Lyft, formerly marketed as Perlane-L, is an injectable gel used to increase volume and smooth wrinkles in the face. With t
- ASDS: Laser Hair Removal On the Risehttps://practicaldermatology.com/news/asds-laser-hair-removal-on-the-rise/2458918/More patients are seeking laser treatments to permanently remove unwanted hair, a new American Society for Dermatologic Surgery (ASDS) survey shows. About 633,000 laser hair removal procedures were performed by ASDS members last year – a 27 percent increase from 2013 and a 51 percen
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- ASDSA Supports FDA Fillers Directivehttps://practicaldermatology.com/news/asdsa-supports-fda-fillers-directive/2458935/A recent FDA directive that soft-tissue filler manufacturers include additional precautions on product labels underscores the importance of patients seeking expert physicians for their treatments, according to the American Society for Dermatologic Surgery Association (ASDSA). The FDA is a
- AcneCareMD Website Launcheshttps://practicaldermatology.com/news/acnecaremd-website-launches/2458957/Jamie Altman, MD, owner and president of Aesthetic Dermatology Associates, PC, in Media and Paoli, PA, launched AcneCareMD.com, a secure telemedicine website to provide acne care to patients across Pennsylvania via
- RXi Pharmaceuticals Receives FDA Orphan Drug Designation for Samcyprone for Melanomahttps://practicaldermatology.com/news/rxi-pharmaceuticals-receives-fda-orphan-drug-designation-for-samcyprone-for-melanoma/2458964/The FDA granted RXi Pharmaceuticals Corporation Orphan Drug Designation of its second clinical candidate, Samcyprone™, for the treatment of malignant melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone™ is bei
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- MDRejuvena Launches Novel Product Line Focused on Skin Healthhttps://practicaldermatology.com/news/mdrejuvena-launches-novel-product-line-focused-on-skin-health/2458978/MDRejuvena, Inc. launched its novel, proprietary product line at the American Academy of Dermatology Meeting in San Francisco. MDRejuvena's product line, designed to rejuvenate, enhance, and maintain skin health, incorporates Phytochromatic MDT Complex, a proprietary, patented, plant-derived
- Signum Dermalogix Out-Licenses SIG990 to Dermata Therapeutics for Topical Treatment of Rosaceahttps://practicaldermatology.com/news/signum-dermalogix-out-licenses-sig990-to-dermata-therapeutics-for-topical-treatment-of-rosacea/2458979/Signum Dermalogix, Inc. entered into an agreement with Dermata Therapeutics to develop a topical product for the treatment of patients with rosacea. SIG990 is a novel, first-in-class anti-inflammatory compound, which has the potential to both reduce erythema and decrease the papules and pustules
- Dermira Presents Clinical Data for DRM01 Acne Programhttps://practicaldermatology.com/news/dermira-presents-clinical-data-for-drm01-acne-program/2458981/Dermira, Inc. presented clinical data from its DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne